# **ERSTE STOCK BIOTEC VT**

Biotechnology stocks with a focus on the US market

ISIN: AT0000A0XYP0

## Overview

### 2024/03/19 NAV 12,931.8300

**Difference** 0.04% (4.54)


General attributes	
Fund type	Equity Funds
Investment company	Erste Asset Management GmbH
Currency	CZK
Туре	<u>VT</u>
Begin of subscription period	-
Inception	2000/04/17
Licenced in	AT,CZ
Duration of fund	open end
Distribution	06/15
Total assets	249,329,515.76 EUR
Fiscal year	03/15 - 03/14
Initial charge	3.00%
Management fee	1.80%
Ongoing charges	2.06%
Minimum investment	According to offer
Account number	-
Recommended holding period	At least 6 years
Investor experience	-
Investor tolerance	<u>5 (scale 1-7)</u>
Disclosure Regulation	Article 8

Initial charge represents a % of the value of the current fund share unit price and is charged once upon making the investment. Management Fee and Ongoing Charges represent costs paid from the assets of the mutual fund on an annual basis (per annum).



#### Performance goal and investment strategy

The ERSTE STOCK BIOTEC invests primarily in companies in the developed markets from the field of biotechnology. The fund's investment process is based on fundamental business analysis. The majority of companies in this area can be found in the United States. As a result, Pacific and European equities tend to play a subordinated role in the fund. A hedge against foreign currency risks is generally not provided, but is possible.





### Upozornění na riziko podle rakouského zákona o investičních fondech 2011

Unless explicitly noted otherwise, performance figures for periods of less than ten years always start from the launch of the fund. Performance figures for periods of less than 12 months in particular are not indicative of a fund's development due to their short-term nature.

ERSTE STOCK BIOTEC may exhibit increased volatility due to the composition of its portfolio: i.e. the unit value can be subject to significant fluctuations both upwards and downwards within short periods of time.

Top holdings (2024/02/29)					
ISIN	Name	Currency	%FA		
-	REGENERON PHARMAC.DL-,001	-	8.94		
-	VERTEX PHARMAC. DL-,01	-	8.17		
-	GILEAD SCIENCES DL-,001	-	6.98		
-	ASTRAZENECA DL-,25 SP.ADR	-	6.28		
-	AMGEN INC. DL-,0001	-	4.21		
-	BIOGEN INC. DL -,0005	-	4.20		
-	VIKING THERAPEUT.DL -,005	-	2.80		
-	BIOMARIN PHAR. DL-,001	-	2.78		
-	ARGENS SE SP.ADR/1 -,10	-	2.47		
-	MADRIGAL PHARMAC. DL-,01	-	2.30		

Holdings by country (2024/02/29)				
	86.76 %	United States of America		
	7.01 %	United Kingdom		
	2.81 %	Netherlands		
	1.03 %	Denmark		
	1.03 %	Canada		

Holdings by currency (2024/02/29)		
99.32 % USD		
0.68 % EUR		

Please read the disclaimer at the end of the document.



Percentage holdings by sector (2024/02/29)				
	83.47 %	Biotechnology		
	11.73 %	Pharmaceuticals		
	4.22 %	Life Sciences Tools & Services		
	0.59 %	Health Care Services		

#### **Disclaimer**

The full names of the open-ended mutual funds and complete product information are provided in the statutes (prospectuses) of the funds. The information stated herein is of the nature of a promotional message. The information stated in this message is not an investment recommendation or investment advice since it does not take into account the specific situation of specific investors. The value of the financial instruments may rise and fall, while there is no guarantee of a return on the originally invested amount. Past performance is no guarantee of the same performance in a future period. A visitor to this website may be outside the target market of the financial instruments stated herein. We recommend that you consult your specific investment plan with an expert advisor who will verify that the planned investment will be commensurate with your knowledge and experience, that it will be in accordance with your needs, characteristics and goals, financial circumstances or relation to risk, and will familiarise you with all possible risks of a specific investment opportunity.

